Actuate Therapeutics (ACTU) began trading on the Nasdaq on Tue 13 Aug 24

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. 

The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 11
• Incorporated in 2015 
• Based in Fort Worth, Texas
• https://actuatetherapeutics.com
• Ticker: ACTU